X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (104) 104
index medicus (103) 103
pulmonary disease, chronic obstructive - drug therapy (92) 92
respiratory system (88) 88
tiotropium (76) 76
obstructive pulmonary-disease (74) 74
chronic obstructive pulmonary disease (72) 72
once-daily indacaterol (62) 62
treatment outcome (60) 60
lung diseases, obstructive (58) 58
indacaterol (57) 57
pulmonary disease, chronic obstructive - physiopathology (53) 53
copd (52) 52
bronchodilator agents - therapeutic use (49) 49
administration, inhalation (48) 48
bronchodilator agents - administration & dosage (48) 48
efficacy (47) 47
double-blind (44) 44
safety (41) 41
drug therapy (39) 39
female (36) 36
male (36) 36
middle aged (36) 36
pharmacology & pharmacy (33) 33
aged (32) 32
bronchodilator agents - adverse effects (32) 32
twice-daily salmeterol (30) 30
adrenergic beta-2 receptor agonists - therapeutic use (29) 29
formoterol (28) 28
indans - therapeutic use (28) 28
once-daily tiotropium (28) 28
quinolones - therapeutic use (28) 28
salmeterol (27) 27
adrenergic beta-2 receptor agonists - administration & dosage (26) 26
diseases of the respiratory system (26) 26
indans - administration & dosage (26) 26
lung-function (26) 26
quinolones - administration & dosage (26) 26
international journal of chronic obstructive pulmonary disease (25) 25
pulmonary disease, chronic obstructive - diagnosis (25) 25
quality of life (25) 25
review (25) 25
bronchodilators (24) 24
drug therapy, combination (24) 24
forced expiratory volume (24) 24
lung - drug effects (24) 24
lung - physiopathology (24) 24
pulmonary/respiratory (24) 24
adrenergic beta-2 receptor agonists - adverse effects (23) 23
care and treatment (23) 23
respiratory tract diseases (23) 23
muscarinic antagonists - administration & dosage (22) 22
severity of illness index (22) 22
dosage and administration (21) 21
double-blind method (21) 21
muscarinic antagonists - adverse effects (21) 21
muscarinic antagonists - therapeutic use (21) 21
drug combinations (20) 20
fixed-dose combination (20) 20
pharmacological characterization (20) 20
asthma (19) 19
forced expiratory volume - drug effects (19) 19
pulmonary and respiratory medicine (19) 19
randomized controlled trials as topic (19) 19
tiotropium bromide (19) 19
drug administration schedule (18) 18
placebo (18) 18
respiratory agents (17) 17
analysis (16) 16
indans - adverse effects (16) 16
once-daily nva237 (16) 16
quinolones - adverse effects (16) 16
copd patients (15) 15
dose-response relationship, drug (15) 15
dyspnea (15) 15
glycopyrrolate - administration & dosage (15) 15
glycopyrrolate - adverse effects (15) 15
glycopyrrolate - therapeutic use (15) 15
adult (14) 14
research (14) 14
bronchodilator agents - pharmacology (13) 13
daily aclidinium bromide (13) 13
inhaled corticosteroids (13) 13
mortality (13) 13
original research (13) 13
time factors (13) 13
cardiac & cardiovascular systems (12) 12
exacerbations (12) 12
fixed-dose combinations (12) 12
glycopyrronium (12) 12
laba (12) 12
lung hyperinflation (12) 12
olodaterol (12) 12
scopolamine derivatives - therapeutic use (12) 12
studies (12) 12
umeclidinium/vilanterol 62.5/25 mcg (12) 12
aclidinium bromide/formoterol fumarate (11) 11
beta-agonist (11) 11
bronchodilation (11) 11
clinical trials (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of COPD, ISSN 1176-9106, 07/2013, Volume 8, pp. 353 - 363
Journal Article
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 142, Issue 5, pp. 1104 - 1110
Background Bronchodilators are central to the symptomatic management of patients with COPD. Previous data have shown that inhaled indacaterol improved numerous... 
Pulmonary/Respiratory | BETA-AGONIST | DIAGNOSIS | OBSTRUCTIVE PULMONARY-DISEASE | EFFICACY | SAFETY | RESPIRATORY SYSTEM | ONCE-DAILY INDACATEROL | SALMETEROL | CRITICAL CARE MEDICINE
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 05/2010, Volume 53, Issue 9, pp. 3675 - 3684
Following a lipophilicity-based hypothesis, an 8-hydroxyquinolinone 2-aminoindan derived series of beta(2)-adrenoceptor agonists have been prepared and... 
BETA-ADRENOCEPTOR AGONISTS | GLOBAL STRATEGY | ONCE-DAILY BETA-AGONIST | FORMOTEROL | CHEMISTRY, MEDICINAL | PHARMACOLOGICAL CHARACTERIZATION | ASTHMA | BRONCHODILATOR EFFICACY | DURATION | DISCOVERY | SALMETEROL
Journal Article
Pulmonary Pharmacology & Therapeutics, ISSN 1094-5539, 2017, Volume 45, pp. 19 - 33
Abstract In this review, we summarize the rationale for combining long-acting bronchodilators in the management of chronic obstructive pulmonary disease... 
Medical Education | Pulmonary/Respiratory | Human | QVA149 | Indacaterol | Dual bronchodilation | Glycopyrronium | COPD | BLOOD EOSINOPHILS | PHARMACOLOGICAL CHARACTERIZATION | INHALED CORTICOSTEROIDS | SALMETEROL-FLUTICASONE | ONCE-DAILY TIOTROPIUM | OBSTRUCTIVE PULMONARY-DISEASE | AUTORADIOGRAPHIC VISUALIZATION | TO-SEVERE COPD | RESPIRATORY SYSTEM | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | FIXED-DOSE COMBINATION | Indans - adverse effects | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Muscarinic Antagonists - adverse effects | Pulmonary Disease, Chronic Obstructive - physiopathology | Quinolones - pharmacology | Quinolones - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Muscarinic Antagonists - pharmacology | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Administration, Inhalation | Bronchodilator Agents - pharmacology | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Animals | Glycopyrrolate - administration & dosage | Adrenergic beta-2 Receptor Agonists - administration & dosage | Glycopyrrolate - pharmacology | Drug Combinations | Indans - pharmacology | Pulmonary Disease, Chronic Obstructive - drug therapy | Sleep disorders | Medical colleges | Pneumonia | Lung diseases, Obstructive | Sleep | Bacterial pneumonia | Analysis | Respiratory agents | Drug therapy, Combination
Journal Article
International Journal of COPD, ISSN 1176-9106, 10/2013, Volume 8, pp. 501 - 508
Introduction: The BEACON study evaluated the efficacy and safety of QVA149, a once-daily dual bronchodilator containing a fixed-dose combination of the... 
LAMA | Rescue medication | FEV | LABA | COPD | AUC | FEV1 AUC(0-4hours) | rescue medication | LUNG-FUNCTION | COMBINATION | SALMETEROL | TRIAL | ONCE-DAILY NVA237 | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Drug Combinations | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Usage | Patient outcomes | Indacaterol | Dosage and administration | Glycopyrrolate | Drug therapy, Combination | FEV1 AUC0–4 hours | Original Research
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2017, Volume 128, pp. 92 - 101
Abstract Background Although the prevalence of chronic obstructive pulmonary disease (COPD) increases with age, no specific therapeutic approaches are... 
Pulmonary/Respiratory | Elderly | Indacaterol | COPD | CARDIAC & CARDIOVASCULAR SYSTEMS | MU-G | DYSPNEA | 12-WEEK | BETA-AGONIST | 2 DOUBLE-BLIND | RESPIRATORY SYSTEM | ONCE-DAILY INDACATEROL | TIOTROPIUM | HEALTH-STATUS | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Smoking - adverse effects | Prevalence | Prospective Studies | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Randomized Controlled Trials as Topic - methods | Humans | Middle Aged | Netherlands - epidemiology | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Quinolones - pharmacology | Pulmonary Disease, Chronic Obstructive - epidemiology | Adrenergic beta-2 Receptor Agonists - pharmacology | Vital Capacity - drug effects | Clinical Trials, Phase III as Topic | Quinolones - adverse effects | Tiotropium Bromide - administration & dosage | Aged, 80 and over | Female | Indans - administration & dosage | Severity of Illness Index | Double-Blind Method | Formoterol Fumarate - pharmacology | Bronchodilator Agents - pharmacology | Treatment Outcome | Salmeterol Xinafoate - administration & dosage | Tiotropium Bromide - pharmacology | Quinolones - administration & dosage | Adrenergic beta-2 Receptor Agonists - administration & dosage | Dyspnea - drug therapy | Aged | Health Status | Formoterol Fumarate - administration & dosage | Indans - pharmacology | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Analysis | Complications and side effects | Medical research | Medicine, Experimental | Elderly people | Effectiveness | Lung diseases | Salmeterol | Patients | Quality of life | Studies | Dyspnea | Obstructive lung disease | Population | Formoterol | Chronic obstructive pulmonary disease | Safety | Respiration | Active control | Age | Geriatrics
Journal Article